Recursion Pharmaceuticals, Inc. (RXRX) — Financial statements
Income statement, balance sheet, and cash flow for Recursion Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 75↑26.9% | 59↑34.1% | 44↑10.6% | 40↑296.8% | 10 | |
| Cost of Revenue | 121↑167.4% | 45↑6.2% | 43↓11.8% | 48 | 0.00 | |
| Gross Profit | -46↓440.2% | 14↑955.2% | 1↑115.0% | -9↓185.9% | 10 | |
| Operating Expenses | ||||||
| R&D Expenses | 425↑35.3% | 314↑30.3% | 241↑54.9% | 156↑15.1% | 135 | |
| General & Administrative Expenses | 177↓0.9% | 178↑60.8% | 111↑35.8% | 82↑41.5% | 58 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 177↓0.9% | 178↑60.8% | 111↑35.8% | 82↑41.5% | 58 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -0.70↓331.5% | -0.16↑9.0% | -0.18 | |
| Operating Expenses | 602↑22.2% | 493↑40.2% | 351↑48.2% | 237↑23.0% | 193 | |
| Total Costs & Expenses | 723↑34.4% | 538↑36.5% | 394↑38.0% | 285↑48.1% | 193 | |
| Operating Results | ||||||
| Operating Income | -648↓35.3% | -479↓36.8% | -350↓42.5% | -246↓34.4% | -183 | |
| Depreciation & Amortization | 84↑129.4% | 36↑49.6% | 24↑107.6% | 12↑39.9% | 8 | |
| EBITDA | -559↓31.1% | -427↓38.7% | -308↓35.1% | -228↓30.0% | -175 | |
| EBIT | -643↓38.8% | -463↓39.5% | -332↓38.7% | -239↓30.5% | -184 | |
| Interest & Other Income | ||||||
| Net Interest Income | 21↑47.9% | 14↓25.4% | 19↑206.8% | 6↑315.3% | -3 | |
| Interest Income | 23↑44.6% | 16↓17.6% | 19↑205.7% | 6↑8467.1% | 0.07 | |
| Interest Expense | 2↑15.1% | 2↑1520.6% | 0.10↑76.4% | 0.06↓98.1% | 3 | |
| Non-Operating Income | -5↑68.0% | -16↑12.4% | -18↓185.9% | -6↓938.6% | 0.75 | |
| Other Income / Expenses | 3↓77.2% | 14↓20.7% | 18↑186.9% | 6↑268.8% | -4 | |
| Income Before Tax | -645↓38.8% | -465↓39.9% | -332↓38.7% | -239↓28.4% | -186 | |
| Income Tax Expense | -0.14↑87.9% | -1↑72.3% | -4 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -645↓39.1% | -464↓41.3% | -328↓37.0% | -239↓28.4% | -186 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -645↓39.1% | -464↓41.3% | -328↓37.0% | -239↓28.4% | -186 | |
| Bottom-Line Net Income | -645↓39.1% | -464↓41.3% | -328↓37.0% | -239↓28.4% | -186 | |
| EPS (Basic) | -1.44↑14.8% | -1.69↓7.0% | -1.58↓16.2% | -1.36↓29.5% | -1.05 | |
| EPS (Diluted) | -1.44↑14.8% | -1.69↓7.0% | -1.58↓16.2% | -1.36↓29.5% | -1.05 | |
| Weighted Average Shares | 447↑63.2% | 274↑31.9% | 208↑18.4% | 176↑3.1% | 170 | |
| Weighted Average Diluted Shares | 447↑63.2% | 274↑31.9% | 208↑18.4% | 176↑3.1% | 170 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.